Hta Policies

❓ How is Portugal’s approval of ublituximab reshaping access to multiple sclerosis therapies? The decision introduces new restrictions that could limit patient options and complicate market entry for innovative MS treatments. Explore the full implications for healthcare access and regulatory strategy. #SyenzaNews #pharmaceuticals #HealthcareInnovation #MarketAccess #healthcarepolicy

Portugal's INFARMED has blocked public funding for Datroway in breast cancer, citing insufficient added value.

How is Portugal expanding access to advanced prostate cancer therapies? The country has approved reimbursement for the niraparib-abiraterone combination, strengthening patient options in oncology and highlighting progress in pharmaceutical market access. Discover what this means for treatment innovation and healthcare policy. #SyenzaNews #oncology #MarketAccess

How can Health Technology Assessment reshape funding for social care? Our latest analysis explores strategic approaches to HTA-informed funding and the vital role of support networks in building sustainable, equitable social care systems. Read the full piece to see how these strategies are driving meaningful change. #SyenzaNews #HealthEconomics #HealthcareInnovation #costeffectiveness #innovation

🚀 How is Portugal pioneering global standards in AI health governance? By developing forward-thinking regulatory frameworks and ethical guidelines, the country is ensuring responsible AI adoption across healthcare systems while fostering innovation and trust. Discover how these efforts are shaping the future of digital health worldwide. #SyenzaNews #AIinHealthcare #digitalhealth #governance #innovation

How is NICE expanding treatment options for HFpEF patients? The UK’s National Institute for Health and Care Excellence has approved finerenone, giving clinicians a new evidence-based therapy to improve outcomes in heart failure with preserved ejection fraction. This milestone broadens the therapeutic landscape and reinforces the value of targeted drug development. Read the full analysis. #SyenzaNews #pharmaceuticals #HealthcareInnovation #innovation #MarketAccess

Could conditional adoption pathways unlock faster access to better endometriosis diagnostics? 🔍 This piece outlines pragmatic routes—conditional reimbursement, coverage-with-evidence development, and staged rollouts—that balance earlier patient access with real-world evidence generation. It also highlights stakeholder alignment, outcome metrics, and market-access considerations developers and payers need to navigate. Read the full article for actionable frameworks and a checklist to responsibly bring diagnostic innovations to market. #SyenzaNews #HealthTech #clinicaltrials #MarketAccess #healthcarepolicy

What’s standing between innovative health technologies and patients in Portugal? 🔍 Portugal’s market is slowed by fragmented procurement, complex reimbursement pathways, limited real-world evidence, and regional disparities that hinder rapid adoption of HealthTech. The article outlines the key barriers and practical solutions — from centralized HTA and adaptive pricing to early stakeholder engagement and pilot programs — to accelerate access. Read the full analysis to learn how policymakers, providers, and innovators can bridge the gap. #SyenzaNews #HealthTech #HealthcareInnovation #MarketAccess #healthcarepolicy

Could cemiplimab reshape cervical cancer care — and what does that mean for access and value? 🔬 This article unpacks the clinical benefits seen in recent studies, the pricing and reimbursement hurdles limiting patient access, and pragmatic value-based strategies (e.g., managed entry agreements, budget impact framing) for payers and policymakers. Read the full analysis to learn how stakeholders can balance innovation with affordability and improve real-world access. 💡 #SyenzaNews #oncology #HealthEconomics #MarketAccess #costeffectiveness

Ready to rethink how pharmaceutical innovation pays off for Europe? 💡📈 New drugs and smarter R&D strategies are delivering measurable health benefits while boosting economic returns across manufacturing, investment, and market access — but only with the right policy incentives and collaboration between industry and payers. Read the full article to see which policy levers and investment approaches unlock the greatest returns for patients, companies, and economies. #SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #innovation

🩺 Could we finally delay the onset of Type 1 diabetes? NICE has recommended teplizumab for people at high risk (stage 2), marking a potential first disease‑modifying option that can postpone progression to clinical disease — a decision driven by trial benefit, patient selection and cost‑effectiveness considerations. Read the full #SyenzaNews analysis to understand what this means for clinicians, payers and patients — and how implementation might unfold. #SyenzaNews #pharmaceuticals #HealthEconomics #healthcarepolicy #costeffectiveness

How will the EU’s joint scientific consultation change the future of medical devices? 🔍🇪🇺 The article explains how coordinated scientific advice is bringing clearer evidence expectations, streamlined clinical evaluation, and stronger stakeholder engagement — all aimed at faster, safer market access for innovators and manufacturers. Read the full piece to learn what this means for your product strategy and regulatory planning. #SyenzaNews #medicaldevices #regulatoryaffairs #healthcarepolicy #innovation